Always taking RISK - do your own DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
An awesome PP and lots of great information in there, a 70+ page filings.
Read today’s filings bro, lots of good stuff.
Intercorporate Relationships
The Corporation has seven wholly-owned direct and indirect subsidiaries, being ABcann Medicinals, Harvest Medicine, Green Earth, Patients’ Choice, Universal, ABcann Germany and ABcann Australia.
Yup, I see massive expansion soon. ABCann is one of the top financially backed companies in the MJ sector. This is like buying Aurora around $2 before it’s breakout.
I actually prefer silent Ihub boards, it’s always the silent ones that make the noise when no one is paying attention.
Long ABCann
I wonder if the selling of shares of Emerald Health Science is to fund the Nemus. Nemus also filed a FORM D today. https://ih.advfn.com/p.php?pid=nmona&article=76787468
2018-02-23 18:55 ET - News Release
Mr. Stephen Hall of Emerald Health Sciences reports
On Feb. 14, 2018, Emerald Health Sciences Inc. sold, through a secondary offering, two million common shares of Emerald Health Therapeutics Inc.
Immediately before the transaction that triggered the requirement to file this report, the Acquiror had ownership of 43,156,555 Shares, representing approximately 38.79% of then issued and outstanding Shares. Following the transaction that triggered the requirement to file this report, the Acquiror held direct ownership of 41,156,555 Shares representing approximately 35.10% of the issued and outstanding Shares. The Acquiror also holds 8,489,451 common share purchase warrants (the "Warrants"). Assuming the exercise of the Warrants, the Acquiror would own 49,646,006 Shares representing approximately 39.49% of the issued and outstanding Shares (on a partially-diluted basis giving effect only to the exercise of the Warrants).
The Acquiror disposed of the Shares for investment purposes. The Acquiror may sell additional Shares either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.
This news release is being issued pursuant to Part 3 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators. A copy of the report filed by the Acquiror in connection with the acquisition of the Shares is available on the Issuer's SEDAR profile, and it can also be obtained directly from the Acquiror by contacting the number shown above.
2018-02-23 18:55 ET - News Release
Mr. Stephen Hall of Emerald Health Sciences reports
On Feb. 14, 2018, Emerald Health Sciences Inc. sold, through a secondary offering, two million common shares of Emerald Health Therapeutics Inc.
Immediately before the transaction that triggered the requirement to file this report, the Acquiror had ownership of 43,156,555 Shares, representing approximately 38.79% of then issued and outstanding Shares. Following the transaction that triggered the requirement to file this report, the Acquiror held direct ownership of 41,156,555 Shares representing approximately 35.10% of the issued and outstanding Shares. The Acquiror also holds 8,489,451 common share purchase warrants (the "Warrants"). Assuming the exercise of the Warrants, the Acquiror would own 49,646,006 Shares representing approximately 39.49% of the issued and outstanding Shares (on a partially-diluted basis giving effect only to the exercise of the Warrants).
The Acquiror disposed of the Shares for investment purposes. The Acquiror may sell additional Shares either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.
This news release is being issued pursuant to Part 3 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators. A copy of the report filed by the Acquiror in connection with the acquisition of the Shares is available on the Issuer's SEDAR profile, and it can also be obtained directly from the Acquiror by contacting the number shown above.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aEMH-2573023&symbol=EMH®ion=C
Fireworks to begin soon, last day to add or buy IMO, hearing lots coming our way.
Opium Addiction - Global Pipeline Review, H2 2017
Top Companies mentioned
iX Biopharma Ltd
Nemus Bioscience Inc
Novartis AG
Omeros Corp
https://www.newsmaker.com.au/news/369893/opium-addiction-global-pipeline-review-h2-2017#.Wo-EV3CIaEd
Stargardt Disease Therapeutics Market-Opportunity Analysis, 2017 – 2025
Key players operating in stargardt disease therapeutics market include Nemus Bioscience Inc., Acucela Inc., Katairo, Ocata Therapeutics Inc., Sanofi, Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., Copernicus Therapeutics Inc., Grupo Ferrer Internacional SA, Iris Pharma, Ophthotech Corp, ProQR Therapeutics NV.
http://www.mynewsdesk.com/us/pressreleases/stargardt-disease-therapeutics-market-opportunity-analysis-2017-2025-2425685
Thanks bud. With all the institutional holders and now marijuana ETF, XXII is a no brainer at these prices IMO. I have no doubt we will be rewarded big time with FDA looking for a product that 22nd century and their patents.
Long
Good to see 22nd century group be in MARIJUANA ETFS
https://www.theglobeandmail.com/globe-investor/funds-and-etfs/etfs/horizons-new-cannabis-etf-stands-apart-from-competitors/article38002121/
DEA Slapped in Face: American Epilepsy Society Accepts Marijuana Extract Obliterates Seizures in Epileptic Children.
http://thehealthequity.com/dea-slapped-in-face-american-epilepsy-society-accepts-marijuana-extract-obliterates-seizures-in-epileptic-children/
Inquiry into VLN cigarettes
Health Canada has issued a tender notice asking suppliers what it would cost to purchase 1 million very low-nicotine (VLN) cigarettes, reports CBC News. VLN cigarettes, which have less than 0.4 mg of nicotine each, aren’t available in Canada now. The tender notice is meant to find out which companies could make them and at what cost.
It also asks how a million cigarettes could be safely stored, and for how long, without a “deterioration in quality.”
Health Canada spokeswoman Rebecca Purdy said the government issued the tender notice merely to learn more about the availability of “Canadian-style” VLN cigarettes for possible research applications.
Health Canada is reportedly exploring options to reduce the addictive effect of tobacco products.
http://www.tobaccoreporter.com/2018/02/inquiry-into-vln-cigarettes/
Taking the leap
Tabu has already announced plans to purchase a 24-acre property in the Fraser Valley, where it will build a 70,000-square-foot grow facility in the coming months. The company has also secured the rights to bring the design-forward Spliffin
http://botaniqmag.com/2018/01/taking-the-leap/
2018 FDA Nicotine Steering Committee
Nemus full of great news today, the management team knows how to run a successful business, the best is yet to come here. This is awesome news.
GO Nemus
News on EMerald & Nemus PP
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
https://globenewswire.com/news-release/2018/02/16/1357703/0/en/Emerald-Health-Strategic-Majority-Investor-in-Nemus-Bioscience-Completes-Final-Closing-of-Private-Placement-Investment-Ahead-of-Schedule.html
News:
$NMUS Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
https://www.otcdynamics.com/nmus-emerald-health-strategic-majority-investor-in-nemus-bioscience-completes-final-closing-of-private-placement-investment-ahead-of-schedule/
Anything under $5 is a gift, just accumulating
Long
Dissecting the Insider Trading Patterns of 22nd Century Group, Inc. (XXII)
https://stocknewsgazette.com/2018/02/16/dissecting-the-insider-trading-patterns-of-22nd-century-group-inc-xxii-3/
Agreed. I’ve been buying and adding for a while, no need to change things due to volatility. When XXII succeeds, then we will be rewarded big time. Institutional investors ain’t stupid to put this much money on a unknown company with knowing the real value.
Long
From FDA TWITTER HANDLE
If you’d like FDA’s Nicotine Steering Committee to consider a certain topic or policy issue related to therapeutic nicotine, suggest it by April 16.
If you’d like FDA’s Nicotine Steering Committee to consider a certain topic or policy issue related to therapeutic nicotine, suggest it by April 16. https://t.co/rjBjsiRFgQ
— FDA Tobacco (@FDATobacco) February 16, 2018
WATCH: Trudeau Asked Why Cannabis Company Founded By Former Liberal CFO Is Getting Hundreds Of Millions In Secret Cayman Islands ‘Investment’
https://www.spencerfernando.com/2018/02/15/watch-trudeau-asked-cannabis-company-founded-former-liberal-cfo-getting-hundreds-millions-secret-cayman-islands-investment/
Are they headed to China?
Designed for upscale consumers outside the United States, our MAGIC 0 and MAGIC 2 branded cigarettes are made from our proprietary very low nicotine tobacco.
The tobacco in MAGIC 0 contains approximately 95% less nicotine than tobacco in leading cigarette brands formerly referred to in the United States as “light” cigarettes.
MAGIC 0 cigarettes satisfy smokers’ cravings while greatly reducing nicotine exposure and nicotine dependence. And, since they are made from authentic tobacco, they feature a pure, premium tobacco taste.
http://www.xxiicentury.com/magiczero/
All you have to do is look at the institutional buyers on this company and you know you’re sitting on pile of gold.
https://fintel.io/so/us/xxii
February 14th, 2018 – Tabu Equity Investments Announces New Director
http://tabu.co/press-release-february-14th-2018/
Something’s brewing here
Headed back to $4+, good luck all
It was for EMerald health which owns Nemus.
The Company intends to use the net proceeds of the Offering for its production and R&D-related growth plans, working capital and general corporate purposes.
The Investor has also agreed to exercise 3,000,000 warrants of the Company within three days of closing of the Offering. These warrants, issued by the Company to the Investor on January 9, 2018, are exercisable at a price of $6.00 per Common Share at any time prior to January 9, 2021.
The previously announced purchase by the Investor of 2,000,000 Common Shares from Emerald Health Sciences Inc. (“Sciences”), a control person of the Company, at a price of $6.00 per share, has also closed.
People come and go, it’s all good, EMerald closing their PP today will and should effect us somehow since some of that money will be invested into Emerald health science/Nemus for the pipeline
Lol, good riddance to those that sold, long hold here
I wonder if the Asian company is with Santen Pharmaceutical Company Ltd.
http://www.santen.com/en/ir/
If a definitive agreement is reached and signed, the term sheet contemplates that Acasti would receive an upfront payment of US$8 million upon signing, plus potential additional regulatory and commercial milestone payments in excess of US$125 million, and tiered double-digit royalties on net sales
Can’t wait bro, this is nice news indeed. Hopefully Tabu and Goldrea deal closes soon and we start hearing rest of the news and updates on all that Tabu has planned for.
GOLDREA ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF $0.20 UNITS
https://www.stockwatch.com/News/Item.aspx?bid=Z-C:GOR-2568459&symbol=GOR®ion=C
I love the revised pipeline timeline to goals. This is now a game changer with Emerlad in full control. Love this news.
GO NEMUS & Emerlad
Yeah, this one is a head scratcher for me as well, I was hoping we would hear about the Tabu/GOR deal then the Spliffin deal. Maybe Tabu just wants assets like they mentioned on their original PR and then release the rest of the news. I do like what Tabu is doing though.
February 12th, 2018 – Tabu Equity Investments Announces New Agreement
February 12th, 2018 – Vancouver, British Columbia – Tabu Equity Investments Inc. (the “Company”) announces that it has signed a Letter of Intent with OCTAVIA VODKA LTD. allowing TABU to purchase 10% of OCTAVIA with shares issued by TABU, representing a $300,000 purchase price. The company expects to complete a share purchase agreement within 45 days. As part of the deal, OCTAVIA will licence the TABU brand for a special line of vodka, paying TABU an 8% royalty on sales. Further, both companies have agreed to jointly develop an infused vodka product based on current and up and coming rules and regulations regarding infused drinks. Details of which will be announced over the year in time for new regulations regarding infused cannabis beverages. Subsequent transactions may occur over a time span yet to be determined, but it is expected to be part of an overall definitive agreement. Both parties will also explore jointly, the possibility of new variations on infused beverages as they relate to Health Canada regulations.
Tabu Equity Investments Inc. invests in Canadian ACMPR applicants and licensed United States cannabis technology companies, as well as Canadian based support technologies for the cannabis industry. The company website can be found at: www.tabu.co
http://tabu.co/press-release-feb12-2018/